Intercourse success rates of 32 to 46 percent achieved with tadalafil, with good tolerability
FRIDAY, Oct. 12 (HealthDay News) -- In men with complete erectile dysfunction (ED), tadalafil 2.5 and 5 mg once-daily result an in intercourse success rate of 32.4 and 46.4 percent, respectively, according to research published online Oct. 4 in The Journal of Sexual Medicine.
Ridwan Shabsigh, M.D., of the Maimonides Medical Center in New York City, and colleagues conducted a post-hoc, pooled analysis of results from four randomized, double-blind trials evaluating the effects of tadalafil 2.5 or 5 mg compared with placebo in men with complete ED (no successful intercourse attempts at baseline).
After 12 weeks of once-daily treatment with tadalafil, the researchers found that the mean per-patient Sexual Encounter Profile question 3 (SEP3) increased from 0 percent to 32.4 and 46.4 percent with 2.5 and 5 mg tadalafil, respectively. The SEP2 (successful penetration) increased from 21.1 to 48.2 percent and 24.4 to 66.2 percent with 2.5 and 5 mg tadalafil, respectively. The mean International Index of Erectile Function increased significantly with 2.5 and 5 mg tadalafil versus placebo. Compared with placebo, improvements were also noted in intercourse-satisfaction and overall-satisfaction domains. Tadalafil was well tolerated with no increase in adverse events versus placebo.
"Once-daily tadalafil 2.5 or 5 mg significantly enhanced erectile function (versus placebo) across all coprimary and secondary efficacy end points in this analysis, and was generally well tolerated," the authors write.
The four base studies and the reported analysis were sponsored by Eli Lilly; several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly, which manufactures tadalafil.
Abstract
Full Text (subscription or payment may be required)